Viralytics Ltd., of Melbourne, reported additional interim results from its ongoing phase II CALM trial testing oncolytic immunotherapy candidate Cavatak in patients with stage IIIc and stage IV malignant melanoma, with data showing that 19 of 51 (37 percent) evaluable patients demonstrated immune-related progression-free survival at six months after first dose.